GlassScriptPhysician profile
Stephen H Denzer
NPI 1992742654
$3,376.45
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $606 · 2021: $924 · 2022: $739 · 2023: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $684.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $670.01 | 2020-2023 | |
| Lilly USA, LLC | $426.53 | 2019-2023 | Mounjaro, Emgality, Jardiance |
| Astrazeneca Pharmaceuticals LP | $381.40 | 2019-2023 | Brilinta |
| Novo Nordisk INC | $324.11 | 2019-2023 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $278.76 | 2019-2022 | |
| Abbvie INC. | $235.86 | 2021-2023 | Ubrelvy, Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $219.73 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $192.95 | 2021-2023 | Trintellix |
| Amgen INC. | $123.37 | 2019-2023 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $115.21 | 2019-2023 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.47 | 2019-2021 | |
| Pfizer INC. | $73.44 | 2019-2023 | |
| Glaxosmithkline, LLC. | $54.34 | 2019-2023 | Trelegy Ellipta, Arexvy |
| Abbott Laboratories | $42.85 | 2019 | |
| Insmed, INC. | $24.16 | 2023 | Arikayce |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $23.97 | 2019 | |
| Irhythm Technologies, INC. | $23.15 | 2020 | |
| Esperion Therapeutics, INC. | $21.25 | 2021 | |
| Gilead Sciences, INC. | $17.44 | 2019 | |
| Allergan, INC. | $16.45 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Denzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.